JPM Conference Live! Yasheng Medicine, Science and Vietnam Medicine, Baiji Shenzhou and other reports came

Yasheng Pharmaceuticals: Solid apoptosis pipeline, about to move towards the commercialization stage On the evening of January 13th, Asheng Pharmaceuticals Chairman and CEO Dr. Yang Dajun reported on the company's recent development pipeline progress at the JPM Conference.
He summed up many of the milestones the company has made in 2020 under the challenge of the new crown outbreak: submitting the company's first application for a new drug listing in China (HQP1351) and being included in the priority review, a step from research and development to commercialization; HQP1351 was selected for the third time in the ash annual meeting oral report, the data are encouraging; in one year, the FDA granted 9 orphan drug qualifications and 1 fast-track qualification, of which the number of orphan drug qualifications in 2020 is the first in the world in a single year, and the largest in the history of Chinese pharmaceutical companies; the company's apoptosis pipeline important varieties Bcl-2 inhibitor APG-2575 to obtain preliminary clinical concept verification data; First clinical trials in Europe, etc., and global clinical collaborations with AstraZeneta Pharma and MSD.
Asia-Asia Pharmaceutical focus protein-protein interaction target drug research and development field, has a wealth of product pipeline, in the research project has the global "first-in-class" or "best-in-class" potential, has been approved 33 clinical approvals, is conducting more than 40 clinical research around the world.
Especially in the field of apoptosis research and development, Aachen Pharmaceuticals has built a rich variety layout, and for Bcl-2, IAP and MDM2-p53 three key apoptosis pathways, to promote 5 varieties in the study into the clinical stage.
among them, APG-2575 is the company's own research and development of a new oral Bcl-2 selective small molecule inhibitor, is the first in China to enter the clinical stage, developed by a local company Bcl-2 selective inhibitor.
December 2020, ASYE Pharmaceuticals announced the latest clinical advances of APG-2575: clinical studies of relapsed/difficult-to-treat CLL have been conducted in more than 30 patients, and preliminary results show that the objective remission rate (ORR) in assessable patients is 70%.
at this JPM conference, Dr. Yang Dajun further presented the relevant data.
In particular, with regard to the effectiveness of APG-2575, he emphasized two points, one is that in the case of the absolute number of lymphocytes (ALC), an important indicator of effectiveness, three high-risk patients in the group have returned to normal levels after receiving one cycle of treatment, and the other is that the changes in patients can be assessed in terms of the volume of lymph nodes compared to the baseline.
, preclinical data also showed that APG-2575 showed good tumor suppression in BTK-resistant, treatment-specific WM PDX models.
this provides a basis for further exploration of its indications and shows great potential.
, Dr. Yang Dajun said in a speech to the General Assembly that AAST has made many milestones in 2020 under the challenge of the global new crown epidemic, and the strategic effects of the company's "global innovation" are gradually emerging.
will continue to adhere to this strategy, accelerate clinical development at the global level, further strengthen the company's strength in the field of apoptosis new drug research and development, as soon as possible to bring products to market for the benefit of patients.
Pharmaceuticals: Focused on the development of complementary targeted therapies Cotco Pharmaceuticals was established in 2017, is a new generation of complementary targeted drugs to treat immunomedicine-mediated diseases company.
, the company has completed $99.5 million in financing.
conference, Dr. Frederick Beddingfield ,MD, PhD, CEO of Co-Vietnam Pharmaceuticals, presented the company's research areas and the latest developments.
complement system consists of a series of proteins in a cascading reaction that is part of the innate immune system.
complement system can be activated through 3 different paths, namely, classic path, coagulation path and alternative path.
these complex signal path paths also provide multiple target points for treating complement system anomalies.
with its LOGOC drug discovery platform, Cotco Pharmaceuticals is committed to the development of "first-in-class" and potential "best-in-class" complementary therapies.
according to the report, KCNA has established a product pipeline that includes nine projects, of which the leading drug P014 has entered clinical trials in January 2021, and the primary adaptive disorder studied is supplement-mediated kidney disease.
, P014 is a "first-in-class" dual-functional protein designed to suppress both upstream and downstream complement targets.
it provides a powerful and possibly more selective and precise treatment for complement inhibition by regulating two separate speed-limiting steps in the complement-active cascades that are critical to disease development.
addition, P014 has a longer half-life and potency, with the potential to allow patients to self-dosing at home.
18 months, the company plans to extend three complementary targeted therapies to clinical practice, focusing on inflammatory diseases, autoimmune diseases and tumors, the company said in a report.
company's vision is to revolutionized the lives of patients with complementary-mediated diseases by developing more effective, safer and user-easier drugs.
: These potentially critical events in 2021 are worth looking forward to At this JPM conference, Baiji Shenzhou will deliver a speech on January 14 at 5:20 p.m. Eastern Time.
was founded in 2010, Baiji Shenzhou has grown into a global biotechnology company with a unique strategy after ten years of development, and has successfully brought two independently developed anti-cancer drugs Zebutini and Terelliju monoanti to market.
with Chinese mainland 5,000 employees in The United States, Australia and Europe, the company is accelerating its diversification of its pipeline of new cancer therapies.
, according to JPM, Baiji Shenzhou currently has a rich portfolio of more than 30 assets, including more than 10 assets with global rights and more than 20 assets with China/Asia Pacific rights.
, seven approved drugs (including self-developed and externally co-technology products) have been approved, and a total of 15 new drug listing applications (DAs) from seven drugs have been accepted by regulators in four countries and the European Union.
public information also shows that Baiji Shenzhou conducted a total of more than 70 clinical trials in China and around the world, including 27 key or promising registered clinical trials, covering 40 countries and regions on five continents.
, according to PPT, the partnership with Amgen has validated Baiji Shenzhou's global development and commercialization capabilities, including in China.
the partnership is based on a shared vision of working together to fight cancer and accelerate access to important new anti-tumor drugs for patients in China and around the world.
It's worth noting that Baiji Shenzhou has launched or will launch three cancer drugs from Angarve (Dishu monoanti), Kyprolis (injected kafezome) and Blincyto (injected with perintomo) in China.
potentially critical events to look forward to in 2021? Baiji Shenzhou presented these data on PPT: 1) up to 12 commercial products; 2) multiple commercialization and reimbursement opportunities for Reilly pearl monoanti and Zebutini, 3) Zebtinib key Phase 3 trial data for chronic lymphocytic leukemia (CLL), and 4) continuous advances in in-house research and development pipelines such as TIGIT antibody ipocerlimab, Bcl-2 inhibitors, etc.
regulatory reform and expanded health insurance coverage have created historic opportunities for the pharmaceutical industry, according to a report by The JPM of Baiji Shenzhou.
this context, Baiji Shenzhou's development strategy is to build the world's leading innovative biotechnology companies based in China, thereby improving efficacy and drug access for patients around the world.
, they will use China's strengths to become the preferred partner for global clinical development.